Description
Pharmacological action
Pharmacotherapeutic group
The antimicrobial agent is nitrofuran.
CodeATX: A07AX03.
Pharmacological action
Pharmacodynamics
Nifuroxazide is an antimicrobial derivative of nitrofuran. It blocks the activity of dehydrogenases and inhibits the respiratory chain, the three-carboxylic acid cycle and a number of other biochemical processes in the microbial cell. Destroys the membrane of the microbial cell, reduces the production of toxins by microorganisms. Highly active against Campylobacterjejuni, Escherichiacoli, Salmonellaspp, Shigellaspp., Clostridiumperfingens, Vibriocholerae, pathogenic Vibrions and Vibrioparahaemolytique, Staphylococcusspp.
Weakly sensitive to nifuroxazide: Citrobacterspp, Enterobactercloacae, and Proteusindologenes. Resistant to nifuroxazide: Klebsiellaspp, Proteusmirabilis, Providenciaspp, Pseudomonasspp.
Does not upset the intestinal microflora. In case of acute bacterial diarrhea, it restores the intestines. When infected with enterotropic viruses, it prevents the development of bacterial superinfection.
Pharmacokinetics
After oral administration, nifuroxazide is practically not absorbed from the digestive tract and exerts its antibacterial effect exclusively in the intestinal lumen. Nifuroxazide is excreted by the intestines: 20% unchanged, and the rest of the amount of sonyvifuroxazide is chemically altered.
Indications
Acute bacterial diarrhea that occurs without a deterioration in general condition, fever, intoxication.
Contraindications
Hypersensitivity to nifuroxazide, to nitrofuran derivatives and other components of the drug, pregnancy, neonatal period up to 1 month, prematurity, intolerance to fructose, glucose-galactose malabsorption syndrome, sucrose deficiency and isomaltase.
Precautions
Liver diseases, alcoholism, traumatic brain injury, brain diseases, lactation, childhood.
Use during pregnancy and lactation
In animal studies, no teratogenic effect was detected. However, taking nifuroxazide during pregnancy is not recommended as a precaution.
During the period of breastfeeding, breastfeeding may continue if there is a short course of treatment with the drug.
Consult with your doctor.
Special instructions
In the treatment of diarrhea concomitantly with nifuroxazide therapy, rehydration therapy is necessary.
Treatment for children under 3 years of age should be carried out under the supervision of a doctor.
In the case of bacterial diarrhea with signs of systemic damage (general condition worsening, fever, symptoms of intoxication or infection), you should consult a doctor to decide on the appointment of antimicrobial agents of systemic action.
If you experience symptoms of hypersensitivity (shortness of breath, skin rash, itching), stop taking the drug.
Alcohol is not allowed during nifuroxazide therapy.
Due to the content of methyl parahydroxybenzoate, the drug may cause allergic reactions (possibly delayed).
Nifural ® Suspension contains 1000 mg of sucrose in 5 ml. Accordingly, the sucrose content in a single dose of 2.5 ml of the suspension is 0.04165 bread units (XE), and in a single dose of 5 ml – 0.0833 XE.
The daily dose of sucrose is 0.0833 XE when taken 2, 5 ml of suspension 2 times a day and 0.125 XE when taking 2.5 ml of suspension 3 times a day.
The daily dose of sucrose is 0.250 XE when taking 5 ml of suspension 3 times a day and 0.333 XE when taking 5 ml of suspension 4 times a day.
The content of 96% ethanol in the drug Nifural ®suspension is 1%. The minimum single dose of the drug, corresponding to 100 mg of nifuroxazide (2.5 ml of suspension), contains 0.02 g of ethanol (in terms of absolute alcohol), and the maximum daily dose corresponding to 800 mg of nifuroxazide (5 ml of suspension 4 times a day), contains 0.16 g of ethanol (in terms of absolute alcohol).
Effect on the ability to drive vehicles and mechanisms
The drug does not affect the ability to drive vehicles and mechanisms.
Composition of
5 ml suspension contains:
active ingredient:
nifuroxazide 200 mg
excipients:
sucrose (sugar),
sodium hydroxide,
methyl parahydroxybenzoic acid, srdlrd acid (ethyl alcohol) 96%,
purified water.
Dosage and administration
Applied orally.
For dosing, use a dosed spoon of 5 ml, having a graduation of 2.5 ml.
Shake well before use.
For children from 1 to 6 months: 100 mgnifuroxazide (2.5 ml of suspension) 2-3 times a day (interval between doses of 8-12 hours).
For children from 6 months to 3 years: 100 mg of nifuroxazide (2.5 ml of suspension) 3 times a day (interval between doses is 8 hours).
For children from 3 to 6 years: 200 mg of nifuroxazide (5 ml of suspension) 3 times a day
(interval between doses is 8 hours).
For children from 6 to 18 years: 200 mg of nifuroxazide (5 ml of suspension) 3-4 times a day
(interval between doses of 6-8 hours).
Adults: 200 mg of nifuroxazide (5 ml of suspension) 4 times a day
(interval between doses 6 hours).
Duration of treatment 5-7 days, but not more than 7 days. If during the first
3 days of taking no improvement, then you should consult a doctor.
Use the drug only according to the method of use and at the doses indicated in the instructions. If necessary, please consult your
doctor before using the medicine.
Side effects
Allergic reactions (skin rash, urticaria, Quincke’s edema, anaphylactic shock).
If any of the side effects indicated in the instructions are aggravated, or you notice any other side effects not listed in the instructions, inform your doctor.
Drug Interactions
Concomitant use with drugs that cause the development of disulfiram-like reactions, drugs, is not recommended depressing central nervous system function.
If you are taking other medications (including over-the-counter) before using Nifural ®, consult your doctor.
Overdose
Overdose symptoms not known.
Symptomatic treatment.
Storage conditions
At a temperature not exceeding 25 ° C.
Keep out of the reach of children.
Expiration
3 years.
Deystvuyuschee substances
nifuroxazide
Form of Treatment
suspension dlya accepts vnutry
